RT Journal Article
SR Electronic
T1 ASSOCIATION OF HYPERGLYCEMIA WITH HOSPITAL MORTALITY IN COVID-19 PATIENTS WITHOUT DIABETES: A COHORT STUDY
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.31.20185157
DO 10.1101/2020.08.31.20185157
A1 Mamtani, Manju
A1 Athavale, Ambarish M.
A1 Abraham, Mohan
A1 Vernik, Jane
A1 Amarah, Amatur R
A1 Ruiz, Juan P.
A1 Joshi, Amit J.
A1 Itteera, Mathew
A1 Zhukovski, Sara D
A1 Madaiah, Ravi Prakash
A1 Hart, Peter
A1 Kulkarni, Hemant
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.08.31.20185157.abstract
AB Objective Diabetes is a known risk factor for mortality in Coronavirus disease 2019 (COVID-19) patients. Our objective was to identify prevalence of hyperglycemia in COVID-19 patients with and without diabetes and quantify its association with COVID-19 disease course.Research Design and Methods In this observational cohort study, all consecutive COVID-19 patients admitted to John H Stroger Jr. Hospital, Chicago, IL from March 15, 2020 to May 15, 2020 were included. The primary outcome was hospital mortality and the main predictor was hyperglycemia (any blood glucose ≥7.78 mmol/L during hospitalization).Results Of 403 COVID-19 patients studied, 228 (57%) developed hyperglycemia. Of these, 83 (21%) had hyperglycemia without diabetes. A total of 51 (12.7%) patients died. Compared to the reference group no-diabetes/no-hyperglycemia patients the no-diabetes/hyperglycemia patients showed higher mortality (1.8% versus 20.5%, adjusted odds ratio 21.94 (95% confidence interval 4.04-119.0), p < 0.001); improved prediction of death (p=0.0162) and faster progression to death (p=0.0051). Hyperglycemia within the first 24 and 48 hours was also significantly associated with mortality (odds ratio 2.15 and 3.31, respectively). Further, compared to the same reference group, no-diabetes/hyperglycemia patients had higher risk of ICU admission (p<0.001), mechanical ventilation (p<0.001) and acute respiratory distress syndrome (p<0.001) and a longer hospital stay in survivors (p<0.001).Conclusions Hyperglycemia in the absence of diabetes was common (21% of hospitalized COVID-19 patients) and was associated with an increased risk of and faster progression to death. Development of hyperglycemia in COVID-19 patients who do not have diabetes is an early indicator of poor prognosis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was not funded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Institutional Review Board of the Cook County Health, Chicago, IL with waiver of informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this study represent confidential patient-level information that cannot be shared publicly.